Skip to content
Buy This GLP
← Research
Evidence

Oral Semaglutide for Alcohol Use Disorder: The Phase 2 Trial's Missed Endpoint

In 50 adults with moderate-to-severe alcohol use disorder, oral semaglutide did not reduce lab cue-elicited craving, the outcome the trial was built around. Heavy drinking days fell on a secondary measure.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Primary outcome — lab cue-elicited craving, week 6Not significant. Drinks per day: not significant either.Secondary and exploratory outcomes, each row on its own scaleupper boundno effectHeavy drinking days−0.148Drinks per drinking day−0.047Naturalistic craving−0.216

What the oral trial measured

Our review of alcohol and tirzepatide addresses a different drug and a different question. The trial here tested semaglutide for alcohol use disorder.

Schacht and colleagues randomized 50 treatment-seeking adults to oral semaglutide or placebo for eight weeks. At week six, the groups did not differ significantly on the primary craving measure after exposure to a preferred drink. The adjusted difference was −0.614 points (95% confidence interval −3.563 to 2.335) [1].

In the last four weeks, the semaglutide group reported fewer heavy drinking days on a prespecified secondary outcome. The adjusted model coefficient was −0.580 (95% confidence interval −1.012 to −0.148). The difference in drinks per calendar day did not reach statistical significance [1].

Drinks per drinking day and craving in daily life fell on exploratory measures. The trial used a different questionnaire for daily craving than for the primary laboratory measure. The researchers reported confidence intervals without adjusting for multiple comparisons, so the exploratory findings need confirmation [1].

What the injection trial adds

A separate trial recruited 108 adults with alcohol use disorder and obesity. Both groups received cognitive behavioral therapy. After 26 weeks, the share of heavy drinking days fell 13.7 percentage points more with weekly semaglutide injections than with placebo (95% confidence interval 5.4 to 22.0 points more)[2].

Studies of GLP-1 medicines for opioid use disorder ask a different treatment question and use different outcome measures. Even within alcohol research, the injection trial measured heavy drinking days in adults with obesity and the oral trial prioritized a craving score. The two trials cannot establish whether one formulation works better for alcohol use disorder.

The oral trial followed participants for only eight weeks. Its results leave open whether any effect persists on longer treatment or after stopping [1].

Frequently asked

Did semaglutide reduce drinking in this trial?
Heavy drinking days fell on a prespecified secondary measure. The trial did not find a statistically significant difference in its primary lab craving measure or in drinks per calendar day.
Why does a primary outcome matter more than the others?
The primary outcome is chosen before the trial begins and guides the study design. The oral trial did not adjust for multiple comparisons, making its exploratory findings less certain.
How large was the trial?
The oral phase 2 trial randomized 50 adults and followed them for eight weeks. The separate injection trial included 108 adults with both alcohol use disorder and obesity.
What did the authors conclude?
That continued development is warranted. That is a call for a larger trial, not a finding that the drug works for alcohol use disorder.

Sources

  1. [1] Schacht JP, et al. (2026). Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial The American Journal of Psychiatry. PMID 42522065
  2. [2] Klausen MK, et al. (2026). Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial The Lancet. PMID 42070571

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence